Can You Repeat Lu-177 PSMA Therapy? Retreatment Eligibility After Your First Course Ends

This article is for men with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have finished a first course of lutetium Lu-177 vipivotide tetraxetan and are asking what happens if the cancer progresses again.

Quick answer: For many men who responded to their first course of Lu-177 PSMA therapy, a second course - called retreatment or rechallenge - may be possible after disease progresses again. Research published in 2024 found that 57.4 percent of patients who received a rechallenge series achieved a PSA decline of 50 percent or more. Three conditions must be met: you had a prior response, your cancer still shows PSMA expression on a new scan, and your kidney and bone marrow function remain adequate.

What a standard first course of Lu-177 PSMA therapy involves

The VISION trial - which led to FDA approval of lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for mCRPC - studied up to six treatment cycles, with each cycle spaced six weeks apart. Each infusion delivers targeted radiation directly to prostate cancer cells that carry the PSMA protein on their surface. The FDA website has details on the approved use, which has since been expanded.

At the end of those cycles, most men reach a decision point. Sometimes the cancer stays stable and treatment continues. In other cases the PSA starts climbing again, which signals disease progression despite treatment. That is when many men ask: can I do this again?

Until recently, retreatment with Lu-177 PSMA was not part of formal clinical guidelines. But published research from nuclear medicine centers in Germany, Australia, and other countries now gives oncologists a clearer picture of who can be retreated and what to expect.

What the evidence says about retreatment

The most detailed prospective data on rechallenge comes from the REALITY study, published in 2024. Researchers followed 47 men with mCRPC who had achieved a PSA response during their first course of Lu-177 PSMA-617 therapy, then experienced disease progression, and went on to receive at least one rechallenge series. After the first rechallenge series, 57.4 percent of patients achieved a PSA decline of at least 50 percent. The researchers concluded that rechallenge "should be considered as a treatment option in mCRPC patients who previously benefited from PSMA-RLT." The full paper is available at PubMed Central.

A separate study published in the Journal of Nuclear Medicine examined a second course of additional cycles given every four weeks. The research team found the second course was safe and offered "favourable tolerability, response rates, overall survival, and progression-free survival," calling it a "promising alternative for the retreatment of mCRPC patients who have formerly responded well." That study is also at PubMed Central.

The most rigorous prospective retreatment data is still being gathered. The RE-LuPSMA trial (NCT06288113) - a formal phase 2 prospective study - is now actively enrolling men specifically for retreatment with Lu-177 PSMA-617 after prior response and progression. Its primary goal is to measure 12-month overall survival after rechallenge. The published trial protocol is available at PubMed Central. Results from this trial will likely shape how retreatment is offered more broadly in the years ahead.

Most existing retreatment data comes from centers where Lu-177 PSMA was available before FDA approval - particularly in Germany and Australia. The results are positive, but the evidence base is smaller than the data supporting the original six-cycle course from the VISION trial. Clinical expertise matters a great deal when evaluating individual eligibility for retreatment.

Who is most likely to qualify for a second course

Retreatment is not automatic after the first course ends. Your nuclear medicine and oncology team will assess several factors before recommending a second course.

Prior response to the first course

The most important factor is whether your PSA fell during the first course. Most retreatment protocols - including the criteria used in the RE-LuPSMA trial - require a PSA decline of at least 50 percent at some point during the first course. Doctors call this a PSA50 response. It shows your cancer was sensitive to the Lu-177 PSMA radiation and that a similar approach may work again after progression.

If your PSA did not decline during the first course, retreatment is unlikely to help. Your care team will likely explore other treatment options instead.

Continued PSMA expression on a repeat PET scan

Lutetium Lu-177 vipivotide tetraxetan works by targeting cancer cells that express the PSMA protein (prostate-specific membrane antigen). Before a second course can begin, you will need a repeat PSMA PET scan to confirm that your tumors still carry PSMA at levels high enough to be targeted effectively.

Some cancers lose PSMA expression over time - a process called phenotypic switching. This can happen after earlier lines of therapy, including prior Lu-177 PSMA treatment. If a repeat scan shows low or absent PSMA expression, the therapy has no viable target. In that scenario, other treatment approaches become more relevant.

If you are uncertain how to interpret your PSMA PET results, the guide on how to read your PSMA PET scan covers what imaging findings mean in plain language.

Kidney function and bone marrow health

The two organs that receive the most radiation exposure during Lu-177 PSMA therapy are the kidneys and the bone marrow. Your care team will check both carefully before recommending retreatment.

Kidney function - typically measured by creatinine clearance or glomerular filtration rate (GFR) - is critical. The RE-LuPSMA trial excludes patients with creatinine clearance below 50 mL/min. If your kidney function declined significantly during or after the first course, a second course may not be safe.

Your care team will also check your bone marrow function through standard blood counts: white blood cell count, platelet count, hemoglobin, and absolute neutrophil count. Lu-177 PSMA can lower these values during treatment, and if they have not recovered, retreatment carries a higher risk of serious infection or bleeding. Your team will want to see stable or improving counts before moving forward.

For a detailed look at what labs and scans doctors review before any course of treatment, see the guide on pre-therapy blood tests and scans for Lu-177 PSMA eligibility.

General health and performance status

Retreatment studies generally enroll men who are well enough to handle another round of treatment. Performance status - graded on the ECOG scale from 0 (fully active) to 4 (completely dependent) - is part of the eligibility picture. Most retreatment protocols target men scoring 0 or 1, meaning they remain largely independent in daily life.

If your general health has declined after the first course, this does not mean you cannot get retreated later. It may mean waiting for things to stabilize, or exploring interim supportive care, before reassessing retreatment eligibility.

What can disqualify you from retreatment

Several findings may mean a second course is not the right path at this time:

• No PSA response during the first course - your cancer did not respond to Lu-177 PSMA radiation.
• PSMA-negative or very faint PSMA expression on a repeat PET scan - no viable target for the therapy.
• Kidney function that has declined below a safe threshold.
• Persistent bone marrow suppression - blood counts that have not recovered to safe levels.
• Rapidly growing disease in the liver or other visceral organs that may require a faster-acting systemic approach.
• Other active health conditions that make further systemic treatment unsafe right now.

If retreatment is not currently an option, other pathways remain worth exploring - including clinical trials, additional lines of hormone-directed therapy, or combination approaches. A specialist opinion from a nuclear medicine or theranostics center can be helpful if you feel your eligibility has not been fully evaluated.

How long between the first and second course

There is no single fixed waiting period. The RE-LuPSMA trial specifies that patients must have completed at least four cycles of a first course, with no new prostate cancer therapy started within two months of completing it. This allows time to establish whether the disease has truly progressed after the first course ends, rather than treating during a potential ongoing response.

Published case series show intervals between first and second courses ranging from a few months to over a year. Longer intervals - meaning the disease stayed controlled for longer after the first course - have generally been linked to better outcomes on rechallenge. A cancer that remained stable for 12 months before progressing again is likely to respond better to a second course than one that progressed within eight weeks.

Tracking your PSA: the clearest signal

One practical way to prepare for a retreatment conversation is to track your PSA trend carefully after your first course ends. A PSA that fell during treatment, stayed low for several months, and then began rising again is the pattern most associated with benefit from rechallenge. A PSA that never fell - or that rose within weeks of the first cycle - suggests the tumor may not be responding to Lu-177 PSMA and that a different treatment approach may serve you better.

The article on what happens to your PSA levels during Lu-177 PSMA therapy explains what different PSA patterns mean and what to raise with your care team at follow-up appointments.

Where retreatment is available and how to check eligibility

In countries where lutetium Lu-177 vipivotide tetraxetan is approved - the United States, the European Union, the UK, and Australia - you may be able to access retreatment through academic nuclear medicine centers or as part of clinical trials. In India, hospitals experienced in Lu-177 PSMA therapy have performed retreatment in real-world practice for several years, supported by a growing body of international data.

For men in countries where the therapy is not approved or not accessible, traveling to a specialist center is a realistic option - but requires preparation. Before booking flights or appointments, have your most recent PSMA PET scan, blood counts, and kidney function results reviewed by the center that would deliver the retreatment. You can request a Lu-177 eligibility review through Art of Healing Cancer, whose nuclear medicine team can assess your imaging and advise whether a second course is appropriate for your specific situation before you travel.

Questions to ask your doctor before retreatment

When you meet with your oncology or nuclear medicine team after your first course ends, these questions may help focus the conversation:

• Did my PSA decline during my first course, and by how much?
• Is a repeat PSMA PET scan recommended to check whether my disease is still PSMA-positive?
• Have my kidney function and blood counts recovered enough to consider retreatment?
• Am I well enough in terms of general health and performance status?
• Are there clinical trials for retreatment that I might qualify for?
• If retreatment is not suitable right now, what options would you consider next?

If you want an independent assessment of retreatment eligibility - or a second opinion on alternatives if retreatment is not possible - you can submit your recent scans and lab results through the Lutetium Therapy contact form. The team can review your case and advise on next steps, including whether other treatment options may be worth pursuing if a second course of Lu-177 PSMA is not appropriate for you.

When to talk to your doctor

If your PSA has started rising after completing a first course of Lu-177 PSMA therapy, tell your oncologist or nuclear medicine specialist at your next appointment - or sooner if the rise is rapid. The right time to plan retreatment, or to explore alternatives, is while your general health and organ function are still strong. Waiting until the disease is very advanced may narrow the choices available to you. This is particularly important if you are managing care from abroad, as arranging scans, lab work, and specialist reviews takes time.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.